Thomas Rohrs' recent sale of Ichor Holdings shares is the largest insider sale in the past year. The sale, around the current price, isn't alarming but isn't positive either. The absence of insider purchases and history of sales call for caution before buying Ichor Holdings stock.
Ichor Holdings股票讨论
2023年净利转亏，但是市盈率即使按2022年高点计算依然达到17.3，估值没有吸引力。
$艾伯维公司 (ABBV.US)$ $博通 (AVGO.US)$ $BioAtla (BCAB.US)$ $Biora Therapeutics (BIOR.US)$ $DermTech (DMTK.US)$ $Broadwind (BWEN.US)$ $CureVac (CVAC.US)$ $EVgo Inc (EVGO.US)$ $Hepion Pharmaceuticals (HEPA.US)$ $尚乘数科 (HKD.US)$ $Ichor Holdings (ICHR.US)$ $万事达 (MA.US)$ $NextPlay Technologies (NXTP.US)$ $Party City Holdco (PRTY.US)$ $星巴克 (SBUX.US)$
https://ir.camber.energy/sec-filings-email/content/0001477932-21-007159/cei_0.8万.htm
暂无评论